Your browser doesn't support javascript.
loading
Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis.
Aram, Jehan; Francis, Anna; Tanasescu, Radu; Constantinescu, Cris S.
Affiliation
  • Aram J; Division of Clinical Neuroscience, Section of Clinical Neurology, University of Nottingham, Nottingham, UK.
  • Francis A; Division of Clinical Neuroscience, Section of Clinical Neurology, University of Nottingham, Nottingham, UK.
  • Tanasescu R; Department of Neurology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Constantinescu CS; Division of Clinical Neuroscience, Section of Clinical Neurology, University of Nottingham, Nottingham, UK.
Neurol Ther ; 8(1): 45-57, 2019 Jun.
Article in En | MEDLINE | ID: mdl-30506485
ABSTRACT
Multiple sclerosis is an inflammatory neurodegenerative disease of the central nervous system (CNS) and the most frequent cause of non-traumatic disability in adults in the Western world. Currently, several drugs have been approved for the treatment of multiple sclerosis. While the newer drugs are more effective, they have less favourable safety profiles. Thus, there is a need to identify new targets for effective and safe therapies, particularly in patients with progressive disease for whom no treatments are available. One such target is granulocyte-macrophage colony-stimulating factor (GM-CSF) or its receptor. In this article we review data on the potential role of GM-CSF and GM-CSF inhibition in MS. We discuss the expression and function of GM-CSF and its receptor in the CNS, as well as data from animal studies and clinical trials in MS.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Neurol Ther Year: 2019 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Neurol Ther Year: 2019 Document type: Article Affiliation country: